Evaluation of Mood Disorders Under Biologics in Chronic Inflammatory Rheumatic Disease
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-80
SponsorCentre Hospitalier Universitaire de Besancon
About this trial
Chronic inflammatory rheumatic diseases (CIRD) affect many organ systems. Painful sensations within the joints spine, hand and foot deformities, low quality of life and psychosocial status in patients with rheumatoid arthritis, spondyloarthritis and psoriatic arthritis can lead to the development of anxiety and depression. Prevalences of anxiety increase in patients suffering of CIRD, compared with healthy individuals. Another connection has been identified by the links between depression and systemic inflammation. It is proven that higher plasma levels of pro-inflammatory cytokines such as tumor necrosis factor alpha (TNFa) affect neurotransmitter metabolism, with influence on patients mood. The purpose of EMOTION study is therefore to analyze thymic variation under TNFa therapy, as treatment of CIRDs.
Eligibility criteria
Qualifiers
Adult patients (≥18 ; ≤ 80)
Patient with rheumatoid arthritis (RA) according to the ACR 2010 criteria, axial or peripheral spondyloarthritis (SpA) according to ASAS criteria, ankylosing spondylitis (AS) according to the New York criteria or psoriatic arthritis (PsA) according to CASPAR criteria
Signature of informed consent
Affiliation to a French social security or receiving such a scheme
Disqualifiers
Patient having previously received anti-TNFα treatment
Patient with previously diagnosed depressive or psychiatric pathology and / or receiving anti-depressant treatment
Subjects with limited legal capacity.
Subjects judged by the investigator to be unlikely to comply with study procedures
Trial design
Treatments tested in this trial
- Blood sample
Treatment groups
108 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov